Wednesday, February 12th
Seminarraum 1
15:00 Registration opens
16:00 PAMM Committee Meeting (members only)
18.00 Welcome reception & BBQ
Thursday, February 13th
Großer Hörsaal 1 (Main Lecture Hall)
8:45 Opening
Stephan Ludwig, Vice-Rector for Research
Jan-Bart Ravoo, Dean of the Faculty of Chemistry und Pharmacy
Joachim Jose, Director of the Department of Pharmaceutical and Medicinal Chemistry
Frits Peters (Amsterdam), PAMM Chair
9:00 Session 1: Biomarker-Guided Therapies
Chair: Joachim Boos (Münster), Frits Peters (Amsterdam)
9:00 Caroline Dive, Manchester: Prognostic and predictive biomarkers –
how is the field progressing?
9:35 Carmelo Rizzari, Milano: Biomarker-guided therapy: Asparaginase as
an example
10:10 Joseph Ciccolini, Marseille: Cytidine Deaminase as a novel biomarker for
predicting clinical outcome with nucleoside
analogs
10:25 Christian Rolfo, Edegem: Liquid biopsies in Non Small-Cell Lung
Cancer: from preclinical studies towards
clinical application
10:40 Coffee/Tea Break
11:15 Session 2: Drug Discovery I
Chair: Andrzej Skladanowski (Gdansk), Robert Mader (Wien)
11:15 Christophe Melle, Basel: Drug penetration and efficacy modelling in vitro
11:45 Wolfgang Berdel, Münster: Anti-vascular tumor therapy with retargeted
tissue factor
12:05 Christoph Schliemann, Münster: Targeting the Neovasculature in
Hematological Malignancies
12:20 Anna-Elisa Quatrale, Bari: Barasertib for the treatment of metastatic
melanoma: in vitro study
12:35 Lunch Break (Mensa am Ring)
14:00 Session 3: Cancer in the Elderly
Chair: Wim JF Van der Vijgh (Maastricht)
Hans Wildiers, Leuven: Challenges and recent advances in Geriatric
Cancer Therapy
14:50 Reports on Joint PAMM Group Activities
European Paediatric Oncology Consortium (EPOC)
Pharmacokinetics, Pharmacogenetics and -dynamics of Doxorubicin in Children
Miriam Krischke, Münster: Study Design and Objectives
Swantje Völler, Münster: Pharmacokinetics
15:20 Coffee/Tea Break
15:50 Session 4: CESAR Session
Chair: Annette Larsen (Paris)
15:50 Max E. Scheulen: Early Clinical Development
16:10 Ulrich Jaehde, Bonn: PK/PD models as basis for Individualized
Therapies
16:40 Christoph Ritter, Greifswald: Better Insights by Systems Pharmacology?
17:30 EORTC-PAMM Group meeting (for members of the EORTC PAMM group)
19:00 Seminarraum 1: Meeting of the CESAR Präsidium (for members of the CESAR Präsidium)
Friday, February 14th
Großer Hörsaal 1 (Main Lecture Hall)
8:45 Session 4: Modelling & Simulation
Chair: Charlotte Kloft (Berlin), Markus Joerger (St. Gallen)
8:45 Norbert Graf, Saarbrücken: In silico modelling of anti-tumour therapy
9:30 Michael Block, Leverkusen: Contribution of Physiologically-Based
Pharmacokinetic Modelling for Oncology Drug
Development
10:00 Zinia Parra-Guillén, Pamplona: Mathematical model approach to describe
tumour response elicited by immune-
stimulatory based therapeutics in mice
10:15 Coffee/Tea Break
11:00 Session 5: Advances in Paediatric Oncology
Chair: Jörg Ritter (Münster), Alan Boddy (Newcastle)
11:00 Heribert Jürgens, Münster: Recent advances in the treatment of bone
tumours in children and adolescents
11:35 Gareth Veal, Newcastle: Individualization of 13-cis-retinoic acid
treatment for children with high-risk
neuroblastoma.
12:10 Hester N Blufpand, Amsterdam: Carboplatin dosing in children using
estimated glomerular filtration rate:
equation matters
12:25 Martin Michaelis, Canterbury: Testing of SNS-032 in a panel of human
neuroblastoma cell lines with acquired
resistance to a broad range of drugs
12:40 Marc Hotfilder, Münster: Identification and Characterization of
Sarcoma Cancer Stem Cells In Vitro
12:55 Meybrit Rasper, Münster: The value of high-dose chemotherapy in
patients with first relapsed Ewing Sarcoma
11:30 Seminarraum 1: CESAR Business Meeting (for members of the CESAR group)
13:10 Lunch Break (Mensa am Ring) and Poster Viewing
14:40 Session 6: Cancer Drug Discovery II
14:40 Stefan Laufer, Tübingen: Development of mutation-specific
EGFR-Inhibitors
15:20 Ian Hardcastle, Newcastle: Small-molecule modulators of the
MDM2/MDMX-p53binding interaction
as antitumour agents
15:50 Manfred Jung, Freiburg: Histone acetyltransferase inhibitors with
anticancer activity in vivo
16:10 Mathias Tacke, Dublin: Synthesis and Biological Evaluation of
Novel Carbene Metal Complexes as
Potential Anticancer Drugs
16:25 Coffee/Tea Break
17:00 Session 7: Pharmacogenetics in Cancer Therapy
Chair: Fritz Peters (Amste
17:00 Matthias Schwab (Stuttgart): The potential of pharmacogenetics in breast
cancer and other tumour entities
17:30 Alan Boddy, Newcastle: Individualisation in cancer treatment: Is
pharmacogenetics relevant?
18:00 Discussion: Pharmacogenetics as a key for successful
cancer therapy?
20:15 PAMM Dinner: Café Uferlos, Bismarckallee
Saturday, February 15th
9:00 Session 8: Proffered papers
Chair: Georg Hempel (Münster), Andy Gescher (Leicester)
9:00 Christiane Schäfer, Münster: Pooled high-throughput shRNA screens to identify tumour-cell specific therapeutic targets in Ewing sarcoma’
9:15 S.E. Verbrugge, Amsterdam: Acquisition of bortezomib resistance confers loss of preferentially expressed antigen in melanoma (PRAME) recognition by allo-HLA-restricted T cells
9:30 Vijay Raja, Selangor: Jerantinine A, an antitumour indole alkaloid evokes potent G2/M
cell cycle arrest targeting tubulin and polo-like kinase 1
9:45 Marcin Serocki, Gdansk: Synthesis and biological evaluation of functionalized derivatives of batracylin as new antitumor agents
10:00- 10:30 Coffee/Tea Break
10:30 Session 8 continued: Proffered papers
Chair: Gerrit Janssen (Amsterdam), Gareth Veal (Newcastle)
10:30 Diane-Charlotte Imbs, Toulouse: Determination of pazopanib plasma unbound fraction, and its clinical implications
10:45 Leticia G. Leon, La Laguna: Pharmacological studies and genetic characterization of mechanisms underlying resistance to a novel T790M-mutant selective EGFR inhibitor
11:00 Paul Mesange, Paris: VEGF inhibition is accompanied by EGFR activation in CRC models providing a rational for combinations of bevacizumab and erlotinib in the GERCOR phase III DREAM study
11:15Amir Avan, Amsterdam: Crizotinib inhibits tumor growth and cytidine deaminase mediated inactivation of gemcitabine in a novel patient derived orthotopic pancreatic tumors with c-Met overexpression
11:30 R. Xu, Cambridge: Development of a three-dimensional in vitro model to study therapeutic efficacy in pancreatic cancer
12:00 Best presentation and best poster award
12:30 End
Poster Presentations:
P.1:Carolin Schleithoff, Münster: The receptor tyrosine kinase RON in paediatric sarcomas – Function and validation as therapeutic target
P.2: Stephanie Lettermann, Münster: In vivo RNAi Screening Identifies HDAC4 as a Mediator of Chemoresistance in Acute Myeloid Leukemia
P.3: C. Ríos-Luci, La Laguna: DTA0100, a novel synthetic small-molecule microtubule destabilizing agent
P.4: Meriam Ayadi, Paris: Acquired chemoresistane is accompanied by altered expression of stem cell markers in colorectal cancer cells
P.5 Martin Michaelis, Canterbury: The Resistant Cancer Cell Line (RCCL) collection
P.6: Christian Diestelhorst, Münster: Predictive Performance of a Physiologically-Based Pharmacokinetic Model of Busulfan in Children
P.7: Tobias Herz, Münster: Development and Validation of a new analytical method to characterize Peg-asparaginase by flow field-flow fractination
P.8: R.J.Honeywell, Amsterdam: Proof of concept - the determination of subcellular localization of several structurally different tyrosine kinase inhibitors
Sponsors:
Die Veranstaltung wird von der MSD Sharp & Dohme GmbH Deutschland in Höhe von 750€ unterstützt. Als Gegenleistung gewähren wir die Aufstellung eines Standes und die Auslage von Informationsmaterial.
